Paul Becherer is an Infectious Disease physician affiliated with North Carolina Division of Public Health. OpenAlex indexes 32 publications with 1,221 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2304 Wesvill Ct
Suite 240
Raleigh, NC 276072973
Telephone
919-571-1567Provider last certified this registry record 12 Oct 2023.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insmed, Inc.Program year20251 payment
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Cephalosporin Antibacterial100%Ceftriaxone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Use of 3.15% Chlorhexidine Gluconate/70% Alcohol Hub Disinfection to Prevent Central Line-Associated Bloodstream Infections in Dialysis Patients
Journal of the Association for Vascular Access
2019 - Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection)
The Lancet Infectious Diseases
2018 - The Effectiveness of 3.15% Chlorhexidine Gluconate/70% Alcohol Hub Disinfection to Prevent Central Line-Associated Blood Stream Infections
American Journal of Infection Control
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”